{"id":5115,"date":"2025-11-04T21:28:58","date_gmt":"2025-11-04T18:28:58","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5115"},"modified":"2025-11-05T00:18:00","modified_gmt":"2025-11-04T21:18:00","slug":"sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/sarepta-dmd-exon-skipping-therapies-fail-confirmatory-study-stock-price-down\/","title":{"rendered":"Sarepta&#039;n\u0131n DMD Ekzon Atlama Terapileri Do\u011frulay\u0131c\u0131 \u00c7al\u0131\u015fmada Ba\u015far\u0131s\u0131z Oldu, Hisse Senedi Fiyat\u0131 D\u00fc\u015ft\u00fc"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Sarepta Therapeutics&#039;nin zorluklar\u0131 giderek k\u00f6t\u00fcle\u015fiyor. Duchenne kas distrofisi hastalar\u0131nda, ekzon atlama tedavileri olan Vyondys 53 ve Amondys 45&#039;in motor fonksiyonu \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirmedi\u011fini tespit ettiler. &gt;&gt;&gt; <a href=\"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-third-quarter-2025-financial\" target=\"_blank\" rel=\"noreferrer noopener\">Sarepta Duyurusu<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sal\u0131 g\u00fcn\u00fc piyasa \u00f6ncesi i\u015flemlerde biyoteknoloji hisseleri $15.60 seviyesinden i\u015flem g\u00f6rd\u00fc; bu, pazartesi g\u00fcnk\u00fc kapan\u0131\u015f hisse fiyat\u0131 olan $24.45&#039;e g\u00f6re 36% d\u00fc\u015f\u00fc\u015f anlam\u0131na geliyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">William Blair analistleri, Sal\u0131 sabah\u0131 m\u00fc\u015fterilerine yazd\u0131klar\u0131 bir mektupta, Sarepta&#039;n\u0131n iyimserli\u011fine ra\u011fmen, ila\u00e7lar\u0131n deneme bulgular\u0131n\u0131n gelecekleri hakk\u0131nda \u015f\u00fcphe uyand\u0131rd\u0131\u011f\u0131n\u0131 belirttiler. &quot;ESSENCE denemesinin ana hedefine ula\u015famamas\u0131n\u0131 olumsuz bir geli\u015fme olarak de\u011ferlendiriyoruz.&quot; diye eklediler.\u2019<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Y\u00f6netim, Vyondys 53 ve Amondys 45&#039;in bu nedenle pazarlama yetkisini kaybetmeyece\u011finden emin olsa da, biz \u015f\u00fcpheliyiz ve hisse senedinin tepkisinin (mesai saatleri d\u0131\u015f\u0131nda 37% d\u00fc\u015f\u00fc\u015f) yat\u0131r\u0131mc\u0131lar\u0131n bu iki ilac\u0131n gelece\u011fi konusunda da endi\u015feli oldu\u011funu g\u00f6sterdi\u011fine inan\u0131yoruz.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt;&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne i\u00e7in T\u00fcm Klinik Ara\u015ft\u0131rmalar<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sarepta Therapeutics&#8217; difficulties only get worse. In patients with Duchenne muscular dystrophy, the business found that their exon-skipping treatments, Vyondys 53 and Amondys 45, did not considerably enhance motor function. >>> Sarepta Announcement Tuesday&#8217;s pre-market trading saw the biotech selling at $15.60, a 36% decrease from Monday&#8217;s closing share price of $24.45. William Blair analysts [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5117,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[453,77,178,65,394],"class_list":["post-5115","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-amondys-45","tag-exon-skipping","tag-exon-skipping-therapies","tag-sarepta","tag-vyondys-53"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5115"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5115\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5117"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}